NR0B2 and neoplasm: In our study, we found that SHP-1.0, SHP-1.7, and SLP-1.3 exhibited higher anti-tumor activity than other fractions, specifically against B16, HeLa, and A549/HepG2 cells, which may be attributed to their higher molecular weight (>500 kDa).